OUH STUDIES

Studies currently being run within Oxford University Hospitals NHS Foundation Trust.

Showing 61 - 70 of 715 studies

Cancer and neoplasms

Getting Recovery Right After Neck Dissection for Head and Neck Cancer (GRRAND)

Head and neck cancer affects the mouth, throat, salivary glands, voice box, nose or sinuses. Every year over 12,000 people get head and neck cancer. It is the 8th most common form of cancer. Over recent years many more people, particularly young people, have developed head and neck cancers. Many of these cancers are removed surgically. Some people also need radiotherapy or chemotherapy. Treatments are improving and better at getting rid of these cancers. Neck dissection is a common operation ...

GO TO STUDY Go

Respiratory

Airable technology for the monitoring of respiratory mechanics during sleep. A cross-sectional proof-of-concept study

Obstructive sleep apnoea (OSA) is a condition where the throat repeatedly closes during sleep, causing loud snoring and disrupted sleep. This leads to poor sleep quality, excessive sleepiness, and risk of car accidents. OSA also contributes to high blood pressure, heart problems, and higher mortality rates. Around 1 billion adults globally have OSA, including 8 million in the UK, but most are undiagnosed and untreated, risking serious health issues. The best way to diagnose OSA is through an overnight sleep study ...

GO TO STUDY Go

Blood

Evaluating the effects of fibrinogen concentrates in the management of inherited fibrinogen disorders

Patients with the rare inherited bleeding disorders, afibrinogenaemia and dysfibrinogenaemia commonly require concentrated fibrinogen therapy to treat or prevent bleeding. Recent studies have highlighted that each type of fibrinogen treatment works a little differently, in particular in the degree to which a strong blood clot, that doesn't dissolve rapidly, is formed. We have recently studied the different effects of two commercial fibrinogen concentrates (Riastap®and Fibryga®) on clot formation in a patient with afibrinogenaemia. Our report suggests that the specific choice ...

GO TO STUDY Go

Cancer and neoplasms

National Study of Adrenal Tumours

This is a study putting together large numbers of patients with or without a hereditary risk of adrenal tumours including tumours such as adrenocortical carcinoma and phaeochromocytoma/paraganglioma. The purpose is to answer questions about the survival of patients with these rare tumours and to do this, we will collect information on diagnosis and management of these tumours. This data will be best assessed by combing these rare cases at a national level recruiting from centres throughout UK and Ireland. The ...

GO TO STUDY Go

Cardiovascular

Evaluation of a Novel Diagnostic Test for Calcium Release Deficiency Syndrome

Millions of people suffer due to cardiac arrest every year and in many cases, the cause of the cardiac arrest is related to a disorder of the electrical activity of the heart. Calcium Release Deficiency Syndrome (CRDS) is a recently discovered electrical heart disorder that develops due to a genetic change in the RyR2 gene resulting in the low activity of RyR2 protein. Currently, CRDS needs genetic testing to be diagnosed and then the identified RyR2 genetic change needs to ...

GO TO STUDY Go

Neurological

Open Network for Frontotemporal dementia Inflammation REsearch (ON-FIRE)

There are many types of dementia. This research studies the family of illnesses known as Frontotemporal type of dementia. This devastating group of illnesses change behaviour, language, and movement. Frontotemporal dementia often affects younger adults and runs in families. There is long running inflammation in the brain with Frontotemporal dementia – suggesting that anti-inflammatory treatments might slow or prevent decline. However, no two people are the same in their symptoms, or in what drives inflammation. For example, genetics, lifestyle, ethnicity ...

GO TO STUDY Go

Metabolic and Endocrine

UK Islet Autoantibody Registry (UKIAb)

We aim to establish a registry of children young people and adults who are IAb positive. We will use the registry to address the following research questions: 1. What is the lived experience of being IAb positive,or having a child who is IAb positive? 2. What are IAb positive individuals’ and their families’ information and support needs? 3. What are the frequency and risk factors associated with clinical outcomes,including progression to Stage 3 T1D in a UK cohort 4. How does the UK IAb positive cohort compare ...

GO TO STUDY Go

Blood

A comparative observational study to evaluate the safety and effectiveness of Xromi® (hydroxycarbamide oral solution 100mg/ml) for the prevention of vaso-occlusive complications of sickle cell disease in children under 2 years of age.

We are conducting a study to gather more information on the safety and effectiveness of Xromi (hydroxyurea), a liquid medicine licensed to treat sickle cell disease (SCD) in children from 9 months of age. We aim to understand its safety profile and efficacy in preventing serious SCD complications (e.g., pain crises, acute chest syndromes, stroke) in children under 2 years when used in standard care. We will compare medical information collected during routine clinical appointments of children under 2 years who ...

GO TO STUDY Go

Cardiovascular

AVEIR Leadless Pacemaker (LP) UK Registry

AVEIR LP UK Registry is a study collecting data from patients who need to have a leadless pacemaker inserted due to underlying heart diseases. Leadless pacemaker technology promises to revolutionise care of the patients that require pacing. The AVEIR pacemaker is the newest of approved leadless pacemakers. Vigilant surveillance of its use in real clinical practice with respect to the effectiveness and safety of the device, at the time of the procedure as well as in the long-term, is essential ...

GO TO STUDY Go

Respiratory

Exacerbation Prevention in chronic obstructive pulmonary disease (COPD) – obstructive sleep apnoea (OSA) overlap syndrome: The clinical and health economic impact of treating patients with COPD-OSA overlap syndrome and a high risk of future exacerbations with positive airway pressure therapy (PAP) a multicentre randomised controlled trial

Patients with chronic obstructive pulmonary disease-obstructive sleep apnoea (COPD-OSA) overlap syndrome have higher rates of COPD exacerbations compared to patients with similar severity COPD without OSA. It is currently not known whether treating OSA in those with COPD-OSA overlap reduces exacerbation rates. COPD exacerbations are characterised by acute transient worsening of symptoms such as dyspnoea, sputum production, sputum purulence and cough which are above the normal day to day variation in symptom burden and are usually associated with escalation of ...

GO TO STUDY Go